Sensus Healthcare (NASDAQ:SRTS) Stock Price Down 0.7% – Here’s What Happened

Sensus Healthcare, Inc. (NASDAQ:SRTS) shares dropped 0.7% on Friday. The stock traded as low as $2.93 and last traded at $2.95. 13,224 shares traded hands during trading, a decline of 44% from the average session volume of 23,533 shares. The stock had previously closed at $2.97.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SRTS. Weiss Ratings downgraded Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Finally, Lake Street Capital reduced their price objective on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.83.

Sensus Healthcare Trading Down 0.7%

The company’s 50-day moving average is $3.11 and its two-hundred day moving average is $3.30. The stock has a market capitalization of $48.56 million, a P/E ratio of -3.14 and a beta of 1.18.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $4.60 million.

Insider Activity

In other Sensus Healthcare news, Director Eric Sachetta acquired 37,537 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The stock was acquired at an average cost of $3.44 per share, with a total value of $129,127.28. Following the acquisition, the director directly owned 267,480 shares of the company’s stock, valued at $920,131.20. This represents a 16.32% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased 120,171 shares of company stock worth $405,230 in the last three months. Insiders own 10.20% of the company’s stock.

Institutional Trading of Sensus Healthcare

Several hedge funds have recently added to or reduced their stakes in the business. North Star Investment Management Corp. acquired a new position in shares of Sensus Healthcare during the first quarter valued at approximately $500,000. Bank of New York Mellon Corp acquired a new stake in Sensus Healthcare in the second quarter worth approximately $303,000. BlackRock Inc. bought a new position in Sensus Healthcare during the 2nd quarter valued at $252,000. Finally, EP Wealth Advisors LLC bought a new position in Sensus Healthcare during the 2nd quarter valued at $49,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc (NASDAQ: SRTS) develops and markets non-invasive medical devices for dermatology and oncology. The company’s primary focus is superficial radiation therapy, a low-energy X-ray treatment designed to treat conditions affecting or located near the surface of the skin.

Its product portfolio includes the SRT-100 system and related platforms, which are used primarily in the treatment of non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as keloid scars.